- Home
- MSGS vs NUVL Comparison
MSGS vs NUVL Comparison
Compare MSGS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGS
- NUVL
- Stock Information
- Founded
- MSGS 1879
- NUVL 2017
- Country
- MSGS United States
- NUVL United States
- Employees
- MSGS 983
- NUVL N/A
- Industry
- MSGS Services-Misc. Amusement & Recreation
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- MSGS Consumer Discretionary
- NUVL Health Care
- Exchange
- MSGS Nasdaq
- NUVL Nasdaq
- Market Cap
- MSGS 4.5B
- NUVL 5.6B
- IPO Year
- MSGS N/A
- NUVL 2021
- Fundamental
- Price
- MSGS $191.95
- NUVL $73.48
- Analyst Decision
- MSGS Buy
- NUVL Strong Buy
- Analyst Count
- MSGS 1
- NUVL 8
- Target Price
- MSGS $250.00
- NUVL $115.50
- AVG Volume (30 Days)
- MSGS 164.8K
- NUVL 682.1K
- Earning Date
- MSGS 05-05-2025
- NUVL 05-08-2025
- Dividend Yield
- MSGS N/A
- NUVL N/A
- EPS Growth
- MSGS 47.09
- NUVL N/A
- EPS
- MSGS 2.36
- NUVL N/A
- Revenue
- MSGS $1,068,271,000.00
- NUVL N/A
- Revenue This Year
- MSGS N/A
- NUVL N/A
- Revenue Next Year
- MSGS $6.72
- NUVL N/A
- P/E Ratio
- MSGS $80.81
- NUVL N/A
- Revenue Growth
- MSGS 21.45
- NUVL N/A
- 52 Week Low
- MSGS $173.26
- NUVL $55.54
- 52 Week High
- MSGS $237.99
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- MSGS 50.47
- NUVL 54.91
- Support Level
- MSGS $183.58
- NUVL $71.60
- Resistance Level
- MSGS $195.12
- NUVL $74.28
- Average True Range (ATR)
- MSGS 6.42
- NUVL 4.86
- MACD
- MSGS 0.80
- NUVL 1.08
- Stochastic Oscillator
- MSGS 85.46
- NUVL 95.73
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.